0001933414-26-000084
SEC filingPersistent operating losses narrowed slightly in Q1 2026 as R&D efficiency improved post-lorundrostat pivotal program completion, driving a smaller net loss and reduced cash burn while the Company advances toward FDA approval.
Mineralys Therapeutics reported operating income of -$45.3 million in Q1 2026, a 2.0% worsening from -$44.4 million in the prior year quarter. This reflects the Company's ongoing investment in research and development and pre-commercial activities following the conclusion of the lorundrostat pivotal program in Q2 2025. The slight increase in operating loss magnitude underscores persistent expenses in a clinical-stage biopharma with no revenue from product sales since inception.
Net income improved to -$39.3 million from -$42.2 million year-over-year, a 6.8% reduction. This narrowing occurred despite higher operating costs, primarily due to non-operating income that offset some losses. Diluted EPS followed suit, improving 40.5% to -$0.47 from -$0.79, as the per-share impact lessened with changes in outstanding shares and the smaller overall loss. These metrics highlight how non-operating factors are helping to moderate the impact of core operating deficits on shareholder value.